Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Lineage Cell Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Lineage Cell Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bradsher Neal C | Director, 10% Owner | 49,560,992Indirect | Jul 2, 2026 | 1 |
| Jayasuriya Anula | Director | 10,000 | Jul 2, 2026 | 1 |
| Mulroy Michael H. | Director | 298,555 | Jul 2, 2026 | 1 |
| Andrews Deborah J | Director | – | Jul 2, 2026 | 1 |
| Russell Angus C. | Director | – | Jul 2, 2026 | 1 |
| Amin Dipti | Director | 35,000 | Jul 2, 2026 | 1 |
| Culley Brian M | President and CEO | 255,516 | Mar 12, 2026 | 4 |
| Samuel George A. III | General Counsel and Secretary | 31,063 | Mar 6, 2026 | 3 |
| Howe Jill Ann | Chief Financial Officer | 25,500 | Mar 6, 2026 | 1 |
| Broadwood Partners, L.P. | Director, 10% Owner | 49,560,992Indirect | Jan 28, 2025 | 0 |
| Broadwood Capital Inc | 10% Owner | 49,560,992Indirect | Jan 28, 2025 | 0 |
| Bailey Don M | Director | 158,801Indirect | Jul 3, 2024 | 0 |
| Kingsley Alfred D | Chairman | – | Jul 3, 2023 | 0 |
| Hogge Gary S. | SVP,Clinical & Medical Affairs | 7,710 | Mar 10, 2023 | 0 |
| Cook Kevin Leon | Chief Financial Officer | – | Mar 11, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 (view filing) | Mar 12 | Same day | Culley Brian MPresident and CEO | PPurchase | +15.0K | $1.63 | +$24.4K | +6.2%255.5K after | |
| Jan 28, 2025 (view filing)7:49 PM ET | Jan 27 | 1 day | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | +7.89M | $0.76 | +$6.00M | +18.9%49.6M after | |
| Jan 28, 2025 (view filing)7:49 PM ET | Jan 27 | 1 day | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | 0 | – | $0 | 0.0%49.6M after | |
| Jan 28, 2025 (view filing)7:49 PM ET | Jan 27 | 1 day | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | +7.89M | $0.00 | $0 | –7.89M after | Derivative |
| Jan 28, 2025 (view filing)7:49 PM ET | Jan 27 | 1 day | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | +7.89M | $0.00 | $0 | –7.89M after | Derivative |
| Nov 26, 2024 (view filing) | Nov 26 | Same day | Howe Jill AnnChief Financial Officer | PPurchase | +15.0K | $0.59 | +$8.85K | +142.9%25.5K after | |
| Nov 26, 2024 (view filing) | Nov 26 | Same day | Samuel George A. IIIGeneral Counsel | PPurchase | +15.0K | $0.60 | +$9.00K | +208.8%22.2K after | |
| Nov 25, 2024 (view filing) | Nov 22 | 3 days | Mulroy Michael H.Director | PPurchase | +40.0K | $0.57 | +$22.8K | +15.5%298.6K after | |
| Nov 22, 2024 (view filing) | Nov 21 | 1 day | Culley Brian MPresident and CEO | PPurchase | +40.0K | $0.60 | +$24.0K | +25.8%194.8K after | |
| Aug 19, 2024 (view filing) | Aug 16 | 3 days | Howe Jill AnnChief Financial Officer | PPurchase | +10.5K | $0.89 | +$9.35K | New position10.5K after | |
| May 28, 2024 (view filing) | May 24 | 4 days | Culley Brian MPresident and CEO | PPurchase | +10.0K | $1.05 | +$10.5K | +6.9%154.8K after | |
| Feb 8, 2024 (view filing)6:58 PM ET | Feb 6 | 2 days | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | +6.73M | $1.04 | +$7.00M | +19.3%41.7M after | |
| Feb 8, 2024 (view filing)6:58 PM ET | Feb 6 | 2 days | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | 0 | – | $0 | 0.0%41.7M after | |
| Feb 8, 2024 (view filing) | Feb 8 | Same day | Bailey Don MDirector | PPurchaseCommon Shares, no par value | +96.2K | $1.04 | +$100.0K | +153.5%158.8K after | |
| Jan 2, 2024 (view filing) | Dec 29, 2023 | 4 days | Jayasuriya AnulaDirector | PPurchaseCommon Shares, no par value | +10.0K | $1.09 | +$10.9K | New position10.0K after | |
| Apr 4, 2022 (view filing) | Mar 31 | 4 days | Culley Brian MPresident and CEO | PPurchaseCommon Shares, no par value | +6.40K | $1.53 | +$9.79K | +7.0%97.8K after | |
| Mar 29, 2022 (view filing) | Mar 28 | 1 day | Amin DiptiDirector | PPurchaseCommon Shares, no par value | +35.0K | $1.63 | +$57.0K | New position35.0K after | |
| Mar 28, 2022 (view filing) | Mar 25 | 3 days | Culley Brian MPresident and CEO | PPurchaseCommon Shares, no par value | +5.25K | $1.38 | +$7.25K | +6.9%81.3K after | |
| Mar 25, 2022 (view filing)5:56 PM ET | Mar 23-25 | 2 days | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | +930.1K | $1.42 | +$1.32M | +2.7%34.9M after | 3 lots |
| Mar 25, 2022 (view filing)5:56 PM ET | Mar 23-25 | 2 days | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | 0 | – | $0 | 0.0%34.9M after | 3 lots |
| Mar 25, 2022 (view filing) | Mar 24 | 1 day | Mulroy Michael H.Director | PPurchaseCommon Shares, no par value | +7.00K | $1.40 | +$9.80K | +2.8%258.6K after | |
| Dec 30, 2021 (view filing) | Dec 28-29 | 2 days | Hogge Gary S.SVP,Clinical & Medical Affairs | SSaleCommon Shares, no par value | −539.3K | $2.45 | −$1.32M | −100.0%0 after | 3 lots |